{"trials":[{"id":5892,"nct_id":"NCT07791901","title":"High vs. Low-Dose Group-Based Psilocybin-Assisted Therapy (PAT) With or Without Mindfulness-Based (MB) Preparation and Integration for Demoralization in Adults With Advanced Cancer (PAT-MIND): A Pilot Feasibility 2x2 Factorial Multisite Trial","sponsor":"University of Calgary","registry_url":"https://clinicaltrials.gov/study/NCT07791901","tracker_url":"publication.php?id=5892","status":"NOT_YET_RECRUITING","status_label":"Not yet recruiting","status_verified_date":"2026-08","last_update_date":"2026-09-02","start_date":"2026-10-30","primary_completion_date":"2027-12-20","completion_date":"2027-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"FACTORIAL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Advanced Cancer","Demoralization","Existential Distress","Psychological Distress"],"interventions":[{"name":"PEX010 25 mg psilocybin","type":"DRUG"},{"name":"PEX010 5 mg psilocybin","type":"DRUG"},{"name":"Standard Psilocybin-Assisted Therapy","type":"BEHAVIORAL"},{"name":"Mindfulness-Based Psilocybin-Assisted Therapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"69ac64288af5cb5338ec5bcb6ba08a6b7fa1b82e6ac1e239ced6fb2bbb2fb97e","facility":"Arthur Child Comprehensive Cancer Centre","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"dc3875179cb830724fc5f84413b98d92146b4b6cbbf28f85a160567e32905d2c","facility":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002}],"countries":["Canada"]},{"id":3509,"nct_id":"NCT05883540","title":"Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study)","sponsor":"University Hospital, Basel, Switzerland","registry_url":"https://clinicaltrials.gov/study/NCT05883540","tracker_url":"publication.php?id=3509","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-04","last_update_date":"2026-04-29","start_date":"2024-06-09","primary_completion_date":"2027-09","completion_date":"2028-05","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":60,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"SUPPORTIVE_CARE","masking":"QUADRUPLE"},"conditions":["Palliative Care","Pain","Anxiety","Depression","Demoralization","Psychological Distress","Quality of Life","Caregiver Burden","Fear of Death","Existential Distress"],"interventions":[{"name":"Lysergic Acid Diethylamide Tartrate","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"b28ad4c1ff8ff143bf7c2827ef2d114686d3c82f734dbd59191da6544cce398b","facility":"University Hospital Basel, Division of Clinical Pharmacology and Toxicology","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"2609712e4f7c93509e6b3bbd8713f3242d8e8886b7480458304bd6280a3610bb","facility":"University Hospital Geneva, Palliative medicine department","city":"Collonge-Bellerive","region":"","country":"Switzerland","lat":46.250610000000002,"lon":6.20174},{"key":"f23fcd3a56bf1387f2f4eb3ab67dce163cae1cad5a551f60baa5d5c5a6da894b","facility":"Spital Uster AG, Division of Internal Medicine","city":"Uster","region":"","country":"Switzerland","lat":47.34713,"lon":8.7209099999999999},{"key":"90de5e97b9c55b0ae303eb535137dc52bdcbaab9be856fa3b3812a38fcbc8990","facility":"University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007}],"countries":["Switzerland"]},{"id":3641,"nct_id":"NCT06818994","title":"Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study","sponsor":"Gustavo Vazquez","registry_url":"https://clinicaltrials.gov/study/NCT06818994","tracker_url":"publication.php?id=3641","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2026-03","last_update_date":"2026-03-18","start_date":"2026-04-01","primary_completion_date":"2027-06-01","completion_date":"2027-06-01","study_type":"INTERVENTIONAL","phases":["PHASE1"],"enrollment":{"count":15,"type":"ESTIMATED"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Demoralization","Safety"],"interventions":[{"name":"Psilocybin-assisted Psychotherapy","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"73be9e73a15b0a509c30e07498262eb93d5497d1e464edc1a0207267273a032a","facility":"Queen's University","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002}],"countries":["Canada"]},{"id":3599,"nct_id":"NCT05227742","title":"Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health","sponsor":"University of Alabama at Birmingham","registry_url":"https://clinicaltrials.gov/study/NCT05227742","tracker_url":"publication.php?id=3599","status":"WITHDRAWN","status_label":"Withdrawn","status_verified_date":"2026-03","last_update_date":"2026-03-11","start_date":"2023-08-15","primary_completion_date":"2026-03","completion_date":"2026-03","study_type":"INTERVENTIONAL","phases":["EARLY_PHASE1"],"enrollment":{"count":0,"type":"ACTUAL"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Demoralization"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Placebo","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"7ce22b002e53ab5c3978b99f32427c645bc1173311a77a8658068ba9bbf879bc","facility":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006}],"countries":["United States"]},{"id":3520,"nct_id":"NCT04950608","title":"Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study","sponsor":"Yvan Beaussant, MD, MSci","registry_url":"https://clinicaltrials.gov/study/NCT04950608","tracker_url":"publication.php?id=3520","status":"COMPLETED","status_label":"Completed","status_verified_date":"2026-01","last_update_date":"2026-02-17","start_date":"2022-03-09","primary_completion_date":"2024-07-27","completion_date":"2025-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":15,"type":"ACTUAL"},"design":{"allocation":"NA","intervention_model":"SINGLE_GROUP","primary_purpose":"TREATMENT","masking":"NONE"},"conditions":["Hospice","Psilocybin","Demoralization","Terminal Illness","Cancer-related Problem/Condition","Psychotherapy","Terminal Cancer","Cancer Terminal"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Psychotherapy","type":"BEHAVIORAL"}],"substances":["psilocybin"],"sites":[{"key":"206ee54b8eec5bd83c44ff9bdf50d3c675f8537d8c74f1be1ba471dae964c101","facility":"Care Dimensions","city":"Danvers","region":"Massachusetts","country":"United States","lat":42.575090000000003,"lon":-70.930049999999994}],"countries":["United States"]},{"id":3700,"nct_id":"NCT05403086","title":"Pragmatic Trial of Psilocybin Therapy in Palliative Care (PT2PC): A Multicenter Triple-blind Phase 2 Randomized Controlled Trial of Psilocybin Therapy for Demoralized Adults Near the End of Life","sponsor":"Charles S. Grob, M.D.","registry_url":"https://clinicaltrials.gov/study/NCT05403086","tracker_url":"publication.php?id=3700","status":"RECRUITING","status_label":"Recruiting","status_verified_date":"2025-11","last_update_date":"2025-11-25","start_date":"2025-01-19","primary_completion_date":"2026-12-31","completion_date":"2027-12-31","study_type":"INTERVENTIONAL","phases":["PHASE2"],"enrollment":{"count":100,"type":"ESTIMATED"},"design":{"allocation":"RANDOMIZED","intervention_model":"PARALLEL","primary_purpose":"TREATMENT","masking":"QUADRUPLE"},"conditions":["Demoralization"],"interventions":[{"name":"Psilocybin","type":"DRUG"},{"name":"Ketamine","type":"DRUG"}],"substances":["psilocybin"],"sites":[{"key":"0ad263eeae1a75dac732ec21553e04d77ca0a990e5577d37801aa0cdfc72ee7c","facility":"Marin Cancer Care","city":"Greenbrae","region":"California","country":"United States","lat":37.948540000000001,"lon":-122.5247},{"key":"721cc70d44836b7fa9283632bc238d3076c232982cd2852343243f358edfbe43","facility":"University of California, Los Angeles","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"332dc40567d170a508105ad5d90cc0c3fa47296c7aa99226e6588e8748f592ae","facility":"University of San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"38d8694ffd1fa8f9e8c095acaf21b7bd718da3dd6a2d2a4642a6dce4e7784baa","facility":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","lat":33.835850000000001,"lon":-118.34063},{"key":"52db1aeead88bb42011a4764f5c07cbf6c76496768465bd5c4fcd8e25775a003","facility":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001}],"countries":["United States"]}],"facets":{"countries":{"United States":182,"Canada":41,"Switzerland":21,"United Kingdom":18,"France":7,"Denmark":7,"Netherlands":6,"Czechia":5,"Ireland":5,"Sweden":4,"Israel":4,"Germany":3,"Australia":3,"Spain":2,"Brazil":2,"Pakistan":2,"Portugal":2,"Belgium":2,"Poland":1,"Austria":1,"New Zealand":1,"Finland":1,"Jordan":1,"Jamaica":1,"Argentina":1},"sponsors":{"Johns Hopkins University":31,"Yale University":16,"University Hospital, Basel, Switzerland":13,"COMPASS Pathways":9,"University of Wisconsin, Madison":9,"NYU Langone Health":9,"Centre for Addiction and Mental Health":8,"University Health Network, Toronto":5,"University of Calgary":5,"King's College London":5,"University of Washington":5,"Imperial College London":5,"University of Zurich":5,"MycoMedica Life Sciences PBC":4,"Joshua Woolley, MD, PhD":4,"University of New Mexico":4,"Usona Institute":4,"Centre Hospitalier Universitaire de Nīmes":4,"Washington University School of Medicine":4,"University of California, Los Angeles":4,"M.D. Anderson Cancer Center":3,"University of Colorado, Denver":3,"University of California, San Diego":3,"University of Alabama at Birmingham":3,"Sheppard Pratt Health System":3,"Unity Health Toronto":2,"University of British Columbia":2,"Emory University":2,"University of Minnesota":2,"Charles Raison":2,"Yvan Beaussant, MD, MSci":2,"Francisco A Moreno":2,"Ohio State University":2,"Khyber Medical University Peshawar":2,"University of California, Berkeley":2,"Sunstone Medical":2,"Robin Carhart-Harris, PhD, MA":2,"Section for Affective Disorders; Northern Stockholm Psychiatry":2,"Anders Fink-Jensen, MD, DMSci":2,"TRYP Therapeutics":2,"Beersheva Mental Health Center":2,"University of California, San Francisco":2,"Gitte Moos Knudsen":2,"University of Utah":2,"Brown University":1,"National Institute on Aging (NIA)":1,"Brigham and Women's Hospital":1,"Oregon Health and Science University":1,"Peter Hendricks":1,"Centre Hospitalier St Anne":1,"Lakshmi N Yatham":1,"Jennifer Mitchell":1,"McMaster University":1,"ARQ National Psychotrauma Centre":1,"University of Nebraska":1,"Region Skane":1,"VA Office of Research and Development":1,"Rachel Yehuda":1,"Sharmin Ghaznavi":1,"Nathan Brashares Sackett":1,"The University of Texas Health Science Center, Houston":1,"Roswell Park Cancer Institute":1,"Claudio N Soares":1,"Nicky Mehtani, MD, MPH":1,"James J. Peters Veterans Affairs Medical Center":1,"Trent Emerick":1,"University of Southern California":1,"Joshua Rosenblat":1,"Tel-Aviv Sourasky Medical Center":1,"Scottsdale Research Institute":1,"Pontifícia Universidade Católica do Rio de Janeiro":1,"Diamond Therapeutics Inc.":1,"Bruyère Health Research Institute.":1,"Ottawa Hospital Research Institute":1,"University of Pennsylvania":1,"Anthony P King":1,"University of Virginia":1,"Manoj Doss":1,"Alan Davis":1,"University Medical Center Groningen":1,"University of North Carolina, Chapel Hill":1,"Stanford University":1,"Portland VA Research Foundation, Inc":1,"Kyle Greenway":1,"Sunnybrook Health Sciences Centre":1,"Indiana University":1,"Federal University of Latin American Integration":1,"Medical University of Vienna":1,"Gustavo Vazquez":1,"Psyence Australia Pty Ltd":1,"Marissa Raymond-Flesch, MD, MPH":1,"Gabriella Gobbi":1,"Hadassah Medical Organization":1,"Nantes University Hospital":1,"Baylor College of Medicine":1,"Rotem Petranker":1,"University of Chicago":1,"University of Iowa":1,"University College, London":1,"University of Texas at Austin":1,"Charles S. Grob, M.D.":1,"Peggy C Nopoulos":1,"Anna Rose Childress, Ph.D.":1,"Kevin Murnane":1,"University Hospital, Geneva":1,"Healing Advocacy Fund":1,"Maastricht University":1,"Matthew Hicks":1,"National University of Natural Medicine":1,"Icahn School of Medicine at Mount Sinai":1,"Kevin Boehnke":1,"Felix Mueller":1,"University of Otago":1,"Insel Gruppe AG, University Hospital Bern":1,"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center":1,"Central Institute of Mental Health, Mannheim":1,"Filament Health Corp.":1,"Western University, Canada":1,"University Hospital, Ghent":1,"University of Arizona":1,"Clairvoyant Therapeutics":1,"Brugmann University Hospital":1,"Empower Research Inc":1,"University of Sydney":1,"Nova Mentis Life Science Corp":1,"Massachusetts General Hospital":1,"Multidisciplinary Association for Psychedelic Studies":1,"Apex Labs Ltd.":1,"Milan Scheidegger":1,"Lobe Sciences Ltd.":1,"Brain and Cognition Discovery Foundation":1,"The Roots to Thrive Society for Psychedelic Therapy":1,"Cybin Therapeutics Inc.":1,"Halucenex Life Sciences Inc.":1,"Combat Stress":1,"Optimi Health Corporation":1,"New York State Psychiatric Institute":1,"Keith Heinzerling":1,"NWTraumatherapies":1,"Beckley Psytech Limited":1,"Wake Network, Inc.":1,"National Institute of Mental Health, Czech Republic":1,"National Council of Scientific and Technical Research, Argentina":1,"Maryland Oncology Hematology, PA":1,"Joshua Woolley":1,"University of Helsinki":1},"phases":{"PHASE2":157,"PHASE1":112,"EARLY_PHASE1":24,"NA":16,"PHASE3":12},"conditions":{"Healthy":26,"Depression":23,"Major Depressive Disorder":23,"Treatment Resistant Depression":20,"PTSD":13,"Alcohol Use Disorder":13,"Anxiety":13,"Psilocybin":12,"Psychedelic Experiences":9,"Opioid Use Disorder":9,"Post Traumatic Stress Disorder":7,"Depression - Major Depressive Disorder":7,"Obsessive-Compulsive Disorder":6,"Advanced Cancer":6,"Demoralization":6,"Anorexia Nervosa":6,"Cancer":6,"Healthy Volunteers":5,"Depressive Disorder":5,"PTSD - Post Traumatic Stress Disorder":4,"Methamphetamine Use Disorder":4,"Anhedonia":4,"Psychological Distress":4,"Alcohol Use Disorder (AUD)":4,"Hematopoietic and Lymphatic System Neoplasm":4,"Depressive Disorder, Major":4,"Major Depressive Disorder (MDD)":4,"Alcohol Dependence":4,"Depressive Symptoms":3,"Suicidal Ideation":3,"Healthy Volunteer":3,"Stage IV Melanoma":3,"Major Depression":3,"Pain Management":3,"Metastatic Malignant Solid Neoplasm":3,"Chronic Pain":3,"Fibromyalgia":3,"PTSD Symptoms":2,"Nicotine Dependence":2,"Borderline Personality Disorder":2,"Treatment-resistant Depression (TRD)":2,"Stage IV Solid Tumor Cancer":2,"Stage IV Sarcoma of Bone":2,"Stage IV Lymphoma":2,"Endocrine Cancer":2,"Psychedelic Effects in Healthy Volunteers":2,"Depression, Anxiety":2,"Chronic Low-back Pain":2,"Parkinson Disease":2,"Existential Distress":2,"Treatment-Resistant Depression":2,"Aging":2,"Bipolar II Disorder":2,"Suicidality":2,"Malignant Solid Neoplasm":2,"Autism Spectrum Disorder":2,"Migraine":2,"Grief":2,"OCD":2,"Addiction":2,"Tobacco Use Disorder":2,"Substance Use Disorders":2,"Treatment-resistant Depression":2,"Treatment-Resistant Major Depressive Disorder":2,"MDD":2,"Substance Use Disorder (SUD)":2,"Healthy Participants":2,"Anxiety Disorders":2,"Depressive Disorder, Treatment-Resistant":2,"Hallucinogens":2,"Sleep":2,"Burnout, Professional":2,"Migraine Headache":2,"Cluster Headache":2,"Mood Change":2,"Phase I":1,"Alzheimer's Disease":1,"Chronic PTSD":1,"PTSD, Post Traumatic Stress Disorder":1,"Amnestic Mild Cognitive Impairment":1,"Neuropathy":1,"Mood (Psychological Function)":1,"Well Being":1,"Mood":1,"Well-Being, Psychological":1,"Parkinson's Disease (PD)":1,"Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI":1,"Chronic Pelvic Pain":1,"Borderline Personality Pathology":1,"Emotion Dysregulation":1,"Older Adults (65-85 Years)":1,"Music Intervention":1,"Emotional Blunting":1,"Bipolar II Depression":1,"Premenstrual Dysphoric Disorder ( PMDD)":1,"PMDD":1,"Psilocybin-Assisted Psychotherapy":1,"Persisting Symptoms After Concussion":1,"Anhedonia in Healthy Volunteers":1,"Older Adults (50-90 Years)":1,"Post Traumatic Stress Disorder PTSD":1,"Intimate Partner Violence (IPV)":1,"Alzheimer Disease":1,"Mild Cognitive Impairment":1,"Posttraumatic Stress Disorder":1,"Breast Cancer":1,"Ovarian Cancer":1,"Investigating the Importance of the Subjective Psychedelic Experience":1,"Burnout":1,"Burnout, Healthcare Workers":1,"Cannabis Use Disorder, Moderate":1,"Cannabis Use Disorder, Severe":1,"Posttraumatic Stress Disorder (PTSD)":1,"Chronic Low Back Pain (CLBP)":1,"Physical Therapy":1,"Pancreas Cancer":1,"Biliary Tract Cancer":1,"Gastrointestinal Cancer":1,"Longevity":1,"Biomarkers of Aging":1,"Psychological Stress":1,"Depression, Bipolar":1,"Generalized Anxiety Disorder (GAD)":1,"Human Immunodeficiency Virus (HIV)":1,"Amyotrophic Lateral Sclerosis":1,"Spinal Cord Injury":1,"Veteran":1,"Bipolar Depression":1,"Postoperative Pain":1,"Mental Health":1,"Opioid-Related Disorders":1,"Pain Management and Care":1,"Advanced Cancers":1,"Smokers With Chronic Pain":1,"Post-Traumatic Stress Disorder, PTSD":1,"Vagus Nerve Stimulation":1,"Healthy Adults":1,"Functional Neurological Disorder":1,"Healthy Controls":1,"Post-Traumatic Stress Disorder (PTSD)":1,"Distress, Emotional":1,"Perception Disorders":1,"Loneliness":1,"Mood Disorders":1,"Obsessive Compulsive Disorder (OCD)":1,"Depressive Sympotoms":1,"Caregiver Distress":1,"Prolonged Grief Disorder":1,"Neuroimaging":1,"Healthy Participants With Lower-than-average Mental Well-being":1,"Cocaine-Related Disorders":1,"Lung Non-Small Cell Carcinoma":1,"Unipolar Depression":1,"Obsessive - Compulsive Disorder":1,"Substance-Related Disorders":1,"Chemically-Induced Disorders":1,"Stimulant-Use Disorder":1,"COPD (Chronic Obstructive Pulmonary Disease)":1,"ALS (Amyotrophic Lateral Sclerosis)":1,"MS (Multiple Sclerosis)":1,"Atypical Parkinson Disease":1,"Refractory Depression":1,"Cognitive Behavioral Therapy":1,"Palliative Care":1,"Pain":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Amphetamine-Related Disorders":1,"Cocaine Use Disorder":1,"Cannabis Use Disorder":1,"Safety":1,"Fibromyalgia, Primary":1,"Transdiagnostic":1,"Substance Use":1,"IBS - Irritable Bowel Syndrome":1,"Stress Disorders, Traumatic":1,"Stress Disorders, Post-Traumatic":1,"Trauma and Stressor Related Disorders":1,"Mental Disorder":1,"Adjustment Disorder":1,"Adjustment Disorder With Anxious Mood":1,"Cancer Cachexia":1,"Cancer of Endometrium":1,"Cancer of Kidney":1,"Cancer of Prostate":1,"Cancer of the Breast":1,"Cancer of Stomach":1,"Cancer Melanoma Skin":1,"Cancer Pancreas":1,"Placebo - Control":1,"Hospice":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1,"Stroke":1,"Chronic Stroke":1,"Intracerebral Haemorrhage":1,"Intracerebral Haemorrhage (ICH)":1,"Intracerebral Hemorrhage Basal Ganglia":1,"Ischemic Stroke":1,"Ischemic Stroke and Hemorrhagic Stroke":1,"Hemiparesis After Stroke":1,"Hemiplegia Following Ischemic Stroke":1,"Hemiplegia and Hemiparesis":1,"Hemiplegia and/or Hemiparesis Following Stroke":1,"Middle Cerebral Artery Stroke":1,"Major Depressive Diorder":1,"Irritable Bowel Syndrome":1,"Gambling Disorder":1,"Phantom Limb Pain":1,"Stuttering":1,"Self Harm":1,"Opioid Dependence":1,"Alcohol Abuse":1,"Recurrent Depression":1,"Obsessive-compulsive Disorder":1,"Psychogenic Nonepileptic Seizures":1,"Reinforcement, Psychology":1,"Post-Treatment Lyme Disease":1,"Chronic Lyme Disease":1,"Lyme Disease, Chronic":1,"Hematopoietic and Lymphoid Cell Neoplasm":1,"Perception Disturbance":1,"Visual Suppression":1,"Meditation":1,"Microdosing":1,"Personal Experience of Substance-assisted Therapy Using Psilocybin, MDMA, and LSD":1,"Chronic Neuropathic Pain":1,"Neuropharmacological Investigation of Ayahuasca Constituents DMT and Harmine":1,"Alcohol-Related Disorders":1,"Burnout, Caregiver":1,"COVID-19":1,"Moral Injury":1,"Basic Science":1,"Binge Eating Disorder":1,"Stimulant Use Disorder":1,"Disorders of Consciousness":1,"Obsessive-compulsive Disorder (OCD)":1,"Severe Alcohol Use Disorder":1,"Psychotherapy, Group":1,"Fragile X Syndrome":1,"Behavior":1,"Cognitive Dysfunction":1,"Alcoholism":1,"Post-Traumatic Stress Disorder":1,"Post-traumatic Stress Disorder":1,"Post-Traumatic Headache":1,"Side Effect of Drug":1,"QTc Interval":1,"Pharmacokinetics":1,"End of Life":1,"Mild Depression":1,"Moderate Depression":1,"Treatment Resistant Disorders":1,"Amnesia":1,"Mood Disturbance":1,"Sleep Disturbance":1,"Drug Effect":1,"Health, Subjective":1,"Psilocin Toxicity":1,"Psilocybin Toxicity":1,"Psilocybin Causing Adverse Effects in Therapeutic Use":1,"Body Dysmorphic Disorders":1,"Trauma, Nervous System":1,"Short Lasting Unilateral Neuralgiform Headache Attacks":1,"Anxiety and Depression":1,"Religious or Spiritual Problem":1,"Patients":1,"Cognitive Change":1,"Creativity":1,"Altered Waking States of Consciousness in Healthy Humans":1,"Distress":1,"Parkinson Disease Psychosis":1,"Severe Depression":1,"Pharmacologic Actions":1,"Central Nervous System Agents":1,"Therapeutic Uses":1,"Psychotropic Drugs":1},"statuses":{"RECRUITING":103,"COMPLETED":97,"ACTIVE_NOT_RECRUITING":33,"NOT_YET_RECRUITING":33,"UNKNOWN":16,"WITHDRAWN":14,"TERMINATED":7,"ENROLLING_BY_INVITATION":3,"SUSPENDED":2}},"years":{"2022":1,"2023":1,"2024":1,"2025":1,"2026":2},"statuses":{"Recruiting":3,"Not yet recruiting":1,"Withdrawn":1,"Completed":1},"conditions":{"Demoralization":6,"Existential Distress":2,"Psychological Distress":2,"Advanced Cancer":1,"Palliative Care":1,"Pain":1,"Anxiety":1,"Depression":1,"Quality of Life":1,"Caregiver Burden":1,"Fear of Death":1,"Safety":1,"Hospice":1,"Psilocybin":1,"Terminal Illness":1,"Cancer-related Problem/Condition":1,"Psychotherapy":1,"Terminal Cancer":1,"Cancer Terminal":1},"sites":[{"key":"69ac64288af5cb5338ec5bcb6ba08a6b7fa1b82e6ac1e239ced6fb2bbb2fb97e","facility":"Arthur Child Comprehensive Cancer Centre","city":"Calgary","region":"Alberta","country":"Canada","lat":51.050109999999997,"lon":-114.08529},{"key":"dc3875179cb830724fc5f84413b98d92146b4b6cbbf28f85a160567e32905d2c","facility":"Providence Care Hospital","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"b28ad4c1ff8ff143bf7c2827ef2d114686d3c82f734dbd59191da6544cce398b","facility":"University Hospital Basel, Division of Clinical Pharmacology and Toxicology","city":"Basel","region":"","country":"Switzerland","lat":47.558390000000003,"lon":7.5732699999999999},{"key":"2609712e4f7c93509e6b3bbd8713f3242d8e8886b7480458304bd6280a3610bb","facility":"University Hospital Geneva, Palliative medicine department","city":"Collonge-Bellerive","region":"","country":"Switzerland","lat":46.250610000000002,"lon":6.20174},{"key":"f23fcd3a56bf1387f2f4eb3ab67dce163cae1cad5a551f60baa5d5c5a6da894b","facility":"Spital Uster AG, Division of Internal Medicine","city":"Uster","region":"","country":"Switzerland","lat":47.34713,"lon":8.7209099999999999},{"key":"90de5e97b9c55b0ae303eb535137dc52bdcbaab9be856fa3b3812a38fcbc8990","facility":"University Hospital Zurich, Clinic for Radio-Oncology, Competence Centre Palliative Care","city":"Zurich","region":"","country":"Switzerland","lat":47.366669999999999,"lon":8.5500000000000007},{"key":"73be9e73a15b0a509c30e07498262eb93d5497d1e464edc1a0207267273a032a","facility":"Queen's University","city":"Kingston","region":"Ontario","country":"Canada","lat":44.229759999999999,"lon":-76.480980000000002},{"key":"7ce22b002e53ab5c3978b99f32427c645bc1173311a77a8658068ba9bbf879bc","facility":"University of Alabama at Birmingham","city":"Birmingham","region":"Alabama","country":"United States","lat":33.520659999999999,"lon":-86.802490000000006},{"key":"206ee54b8eec5bd83c44ff9bdf50d3c675f8537d8c74f1be1ba471dae964c101","facility":"Care Dimensions","city":"Danvers","region":"Massachusetts","country":"United States","lat":42.575090000000003,"lon":-70.930049999999994},{"key":"0ad263eeae1a75dac732ec21553e04d77ca0a990e5577d37801aa0cdfc72ee7c","facility":"Marin Cancer Care","city":"Greenbrae","region":"California","country":"United States","lat":37.948540000000001,"lon":-122.5247},{"key":"721cc70d44836b7fa9283632bc238d3076c232982cd2852343243f358edfbe43","facility":"University of California, Los Angeles","city":"Los Angeles","region":"California","country":"United States","lat":34.052230000000002,"lon":-118.24368},{"key":"332dc40567d170a508105ad5d90cc0c3fa47296c7aa99226e6588e8748f592ae","facility":"University of San Francisco","city":"San Francisco","region":"California","country":"United States","lat":37.774929999999998,"lon":-122.41942},{"key":"38d8694ffd1fa8f9e8c095acaf21b7bd718da3dd6a2d2a4642a6dce4e7784baa","facility":"Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center","city":"Torrance","region":"California","country":"United States","lat":33.835850000000001,"lon":-118.34063},{"key":"52db1aeead88bb42011a4764f5c07cbf6c76496768465bd5c4fcd8e25775a003","facility":"Sunstone Therapies","city":"Rockville","region":"Maryland","country":"United States","lat":39.084000000000003,"lon":-77.152760000000001}],"enrollment":{"sum":250,"known_trials":6},"registry_checked_at_utc":"2026-10-09 01:24:43"}